Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Has $11.59 Million Stake in Edwards Lifesciences Co. (NYSE:EW)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 28.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 133,302 shares of the medical research company's stock after selling 52,589 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in Edwards Lifesciences were worth $11,592,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in the business. Revisor Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $229,000. Raymond James Financial Services Advisors Inc. increased its holdings in Edwards Lifesciences by 4.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 1,144,581 shares of the medical research company's stock worth $109,376,000 after buying an additional 46,217 shares during the last quarter. Stonegate Investment Group LLC increased its holdings in Edwards Lifesciences by 14.9% in the first quarter. Stonegate Investment Group LLC now owns 14,764 shares of the medical research company's stock worth $1,411,000 after buying an additional 1,920 shares during the last quarter. Confluence Wealth Services Inc. increased its holdings in Edwards Lifesciences by 25.4% in the first quarter. Confluence Wealth Services Inc. now owns 5,354 shares of the medical research company's stock worth $512,000 after buying an additional 1,084 shares during the last quarter. Finally, Invera Wealth Advisors LLC increased its holdings in Edwards Lifesciences by 70.1% in the first quarter. Invera Wealth Advisors LLC now owns 31,078 shares of the medical research company's stock worth $2,970,000 after buying an additional 12,809 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity

In other news, VP Catherine M. Szyman sold 27,000 shares of the company's stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the sale, the vice president now directly owns 34,814 shares of the company's stock, valued at approximately $2,980,774.68. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the company's stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $84.77, for a total transaction of $2,487,999.50. Following the completion of the transaction, the director now owns 4,486 shares of the company's stock, valued at approximately $380,278.22. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Catherine M. Szyman sold 27,000 shares of the company's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total value of $2,311,740.00. Following the transaction, the vice president now directly owns 34,814 shares of the company's stock, valued at approximately $2,980,774.68. The disclosure for this sale can be found here. Insiders sold a total of 237,749 shares of company stock valued at $20,920,934 in the last ninety days. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded up $0.76 during midday trading on Thursday, reaching $85.06. 1,936,563 shares of the company traded hands, compared to its average volume of 3,789,544. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The firm has a market cap of $51.26 billion, a PE ratio of 36.66, a PEG ratio of 3.56 and a beta of 1.10. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The stock's 50-day simple moving average is $90.13 and its 200-day simple moving average is $79.23.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EW has been the topic of several analyst reports. Piper Sandler increased their price target on Edwards Lifesciences from $85.00 to $88.00 and gave the company a "neutral" rating in a report on Friday, April 26th. Oppenheimer increased their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the company an "outperform" rating in a report on Monday, March 18th. Mizuho increased their price target on Edwards Lifesciences from $95.00 to $105.00 and gave the company a "buy" rating in a report on Thursday, April 11th. StockNews.com upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating in a report on Monday. Finally, Morgan Stanley increased their price target on Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, March 21st. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, Edwards Lifesciences has an average rating of "Moderate Buy" and an average price target of $92.71.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.